Home » Topics » BioWorld Science

BioWorld Science
RSS

Innate Pharma initiates phase I study of IPH-5401 with durvalumab in solid tumors

Sep. 12, 2018

Janssen Pharmaceutica presents OGA inhibitors

Sep. 12, 2018

Dual sHE inhibitor/PPAR-gamma agonist shows benefits to treat metabolic syndrome and diabetes in rat

Sep. 12, 2018

Prelude Therapeutics identifies new PRMT5 inhibitors

Sep. 12, 2018

Innate Tumor Immunity synthesizes new NLRP3 agonists for cancer

Sep. 12, 2018

RQx Pharmaceuticals and Genentech present antibacterial compounds

Sep. 12, 2018

SuPAR predicts chronic kidney disease progression in Black Americans

Sep. 12, 2018

Phase III study of Zerbaxa in HABP and VABP meets primary endpoints

Sep. 12, 2018

Trevena patents new delta-opioid receptor modulators

Sep. 12, 2018

Researchers present first-in-human data for AT-04A

Sep. 12, 2018

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 18, 2026.
GLP-1s need technologies for long-term use
BioWorld
For the long-term impact of GLP-1 therapies in obesity to be realized, they must be paired with data and digital tools. While the drugs are effective, challenges...
UTRN gene involved in arthrogryposis, study finds
BioWorld Science
Arthrogryposis multiplex congenita (AMC) is a group of disorders defined by two or more contractures in different body areas; while genes encoding sarcomeric...
HMNC raises $50M series B to prep depression drugs for phase III
BioWorld
HMNC Brain Health GmbH has raised $50 million in the first close of a series B, enabling the company to prepare the way for phase III trials of its two lead...
CFTX-2034 successfully shows promise for post-bariatric hypoglycemia in preclinical research
BioWorld Science
Researchers from Confo Therapeutics NV presented the preclinical characterization of CFTX-2034, a selective somatostatin receptor subtype 5 (SSTR5) agonist...